ACM
DRUG

Atika Capital Management’s Bright Minds Biosciences DRUG Stock Holding History

Atika Capital Management’s Portfolio DRUG Stock Details DRUG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-15,000
Closed -$540K – 70
2024
Q4 		$540K Buy
+15,000
New +$528K 0.06% 83

Other funds holding DRUG

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Atika Capital Management's DRUG Position: Q1 2025 in Review

Atika Capital Management sold out of Bright Minds Biosciences (DRUG) in Q1 2025, closing a stake of 15,000 shares — an estimated $540K sold.

Atika Capital Management first reported a position in DRUG in Q4 2024 and held it in 1 quarter. The position peaked at $540K in Q4 2024. 34 funds tracked by Wall St. Rank hold DRUG as of Q1 2025.

  • Atika Capital Management reported no remaining Bright Minds Biosciences position as of Q1 2025 after selling out during the quarter.
  • Atika Capital Management sold 15,000 Bright Minds Biosciences shares in Q1 2025, an estimated $540K.
  • Atika Capital Management first reported a position in Bright Minds Biosciences in Q4 2024 and held it in 1 quarter.
  • Atika Capital Management's Bright Minds Biosciences position peaked at $540K in Q4 2024.
  • 34 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q1 2025.

Based on Atika Capital Management's 13F filing for Q1 2025, filed 14 May 2025.